-The Times of India NEW DELHI/mumbai: Public outrage against corruption may have been the main factor behind the change of governments at Centre and in Delhi during the past two years, but corruption in the public sector is still rife. India's score in the Corruption Perceptions Index (CPI) for 2015 remained unchanged at 38 as it was in the previous year. As per the scoring system adopted, higher the score points...
More »SEARCH RESULT
Total Matching Records found : 2842
Cartel hoarding dal stocks abroad to jack up prices: IB -Dipak K Dash
-The Times of India NEW DELHI: The Intelligence Bureau (IB) has alerted the government about importers of pulses resorting to cartels to make a killing this year on red lentils (masoor). The report has named companies that are buying masoor in large quantities and cornering stocks in Canada, which is the largest exporter of red lentils to India. According to rough estimates, last year dal importers had reportedly made around Rs 3,500...
More »At Rs 20-30 lakh, transplant of liver available only to rich -Rema Nagarajan
-The Times of India Less than 2% of liver transplants taking place in India happen in public in stituations. This has meant that liver transplants, which cost Rs 20-30 lakh in most cases, are available only to the rich. This is not just an inequitable situation, but an unsustainable one, says a recently-published paper reviewing the status of liver transplants in India. "The future of liver transplantation in India should move toward...
More »RBI asks banks to extend loans to women SHGs at 7% rate
-PTI mumbai: The RBI today asked banks to provide loans up to Rs 3 lakh at 7 per cent interest rate to Women Self-Help Group (SHG) under the National Rural Livelihoods Mission (NRLM)-Aajeevika scheme during 2015-16. “All women SHGs will be eligible for interest subvention on credit up to Rs 3 lakhs at 7 per cent per annum. SHG availing capital subsidy under Swarnjayanti Gram Swarojgar Yojana (SGSY) in their...
More »New diabetes drug cuts cost by 80%
-The Times of India mumbai: Diabetics in the country have something to cheer about. A completely new drug in the 'gliptin' family has disrupted the anti-diabetes market by lowering the cost of therapy for patients by 80%. With the launch of the teneligliptin molecule, the popular gliptin category has witnessed a price erosion of over 80% in the last six months, bringing down the cost for a day's treatment from Rs...
More »
